TIM-3 is highly expressed in peripheral blood and bone marrow exhausted T cells in various hematological malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) however, few reports have demonstrated its clinical significance as monotherapy with TIM-3 inhibitors alone [97,98,99]. Here, HAVCR2 is linked to acute lymphoblastic leukemia.